Distinct Clinical Features of Infectious Complications in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis in the Nagasaki Transplant Group

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 607-615

  Itonaga, Hidehiro ^a,b   Taguchi, Jun ^b   Fukushima, Takuya ^b,c   Tsushima, Hideki ^b   Sato, Shinya ^a   Ando, Koji ^d   Sawayama, Yasushi ^b   Matsuo, Emi ^d   Yamasaki, Reishi ^e   Onimaru, Yasuyuki ^b   Imanishi, Daisuke ^b   Imaizumi, Yoshitaka ^b   Yoshida, Shinichiro ^d   Hata, Tomoko ^b   Moriuchi, Yukiyoshi ^b   Honda, Sumihisa ^b   Miyazaki, Yasushi ^b  

^a Sasebo Shiritsu Sogo Hospital   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^e Nagasaki Rousai Hospital   (Japan)

Author keywords

Adult T cell leukemia lymphoma; Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Infection

Indexed keywords

ACICLOVIR; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; MICAFUNGIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CHICKENPOX; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HERPES SIMPLEX; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTIOUS COMPLICATION; JAPAN; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; T CELL LEUKEMIA;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITRACONAZOLE; JAPAN; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; MYCOSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875547927     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.011     Document Type: Article

References (62)

1. Uchiyama T., Yodoi J., Sagawa K., et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
2. Poiesz B.J., Ruscetti F.W., Gazdar A.F., et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Sci USA 1980, 77:7415-7419.
3. Hinuma Y., Nagata K., Hanaoka M., et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981, 78:6476-6480.
4. Yoshida M., Seiki M., Yamaguchi K., et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984, 81:2534-2537.
5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991, 79:428-437.
6. Yamada Y., Tomonaga M., Fukuda H., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001, 113:375-382.
7. Tsukasaki K., Utsunomiya A., Fukuda H., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007, 25:5458-5464.
8. Utsunomiya A., Miyazaki Y., Yakatsuka Y., et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:15-20.
9. Kami M., Hamaki T., Miyakoshi S., et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukemia/lymphoma. Br J Haematol 2003, 120:304-309.
10. Fukushima T., Miyazaki Y., Honda S., et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:829-834.
11. Okamura J., Utsunomiya A., Tanosaki R., et al. Allogeneic stem-cell transplantation with reduced intensity as novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005, 105:4143-4145.
12. Kato K., Kanda Y., Eto T., et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-1-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant 2007, 13:90-99.
13. Tanosaki R., Uike N., Utsunomiya A., et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T-cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008, 14:702-708.
14. Hishizawa M., Kanda J., Utsunomiya A., et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
15. Kanda J., Hishizawa M., Utsunomiya A., et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012, 119:2141-2148.
16. Ishida T., Hishizawa M., Kato K., et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012, 120:1734-1741.
17. Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood doi:10.1182/blood-2012-07-444372.
18. Suzumiya J., Marutsuka K., Nabeshima K., et al. Autopsy findings in 47 cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture. Japan. Leuk Lymphoma 1993, 11:281-286.
19. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997, 15:15-37.
20. Yasunaga J., Sakai T., Nosaka K., et al. Impaired production of naïve T lymphocytes in human T-cell leukemia virus type I-infected individuals: Its implications in the immunodeficient state. Blood 1993, 97:3177-3183.
21. Chen S., Ishii N., Ine S., et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol 2006, 18:269-277.
22. Ogata M., Satou T., Kawano R., et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia. J Med Virol 2011, 83:702-709.
23. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
24. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
26. Maertens J., Marchetti O., Herbrecht R., et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011, 46:709-718.
27. Engelhard D., Akova M., Boeckh M.J., et al. Bacterial prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:467-470.
28. Kanda Y., Mineishi S., Saito T., et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:689-692.
29. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with Myeloabrative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978-1985.
30. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
31. Boekh M., Bowden R.A., Gooley T., et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999, 93:1781-1782.
32. Tagawa M., Minematsu T., Masuzaki H., et al. Seroepidemilogical survey of cmytpmegalovirus infection among pregnant women in Nagasaki, Japan. Pediatr Int 2010, 52:459-462.
33. Hirota K., Muraguchi K., Watabe N., et al. Prospective study on maternal, intrauterine, and perinatal infections with cytomegalovirus in Japan during 1976-1990. J Med Virol 1992, 37:303-306.
34. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.
35. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
36. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
37. La Rosa A.M., Champlin R.E., Mirza N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32:871-876.
38. Leung A.Y., Suen C.K., Lie A.K., Liang R.H., Yuen K.Y., Kwong Y.L. Quantification of polyoma BK viruria in hemorrhagic cystis complicating bone marrow transplantation. Blood 2001, 8:1971-1978.
39. Yoshikawa T., Suga S., Asano Y., et al. Human herpesvirus-6 infection in bone marrow transplantation. Blood 1991, 78:1381-1384.
40. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetic on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
41. Miyazaki Y., Kuriyama K., Miyawaki S., et al. Cytogenetic heterogenecity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 2003, 120:56-62.
42. Walker C.M., van Burik J.A., De For T.E., Weisdorf D.J. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007, 13:1106-1115.
43. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000, 95:2240-2245.
44. van Burik J.A., Carter S.L., Freifeld A.G., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1487-1498.
45. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: change in epidemiology and risk factors. Blood 2002, 100:4358-4366.
46. Schmidt-Hieber M., Schwarck S., Stroux A., et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010, 9:877-885.
47. Park S.H., Choi S.M., Lee D.G., et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009, 11:413-423.
48. Mohty M., Jacot W., Faucher C., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003, 17:2168-2177.
49. Hoegh-Petersen M., Goodyear D., Geddes M.N., et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant 2011, 46:1104-1112.
50. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
51. Miyakoshi S., Kusumi E., Matsumura T., et al. invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007, 13:771-777.
52. Sashihara J., Tanaka-Taya K., Tanaka S., et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplants. Blood 2002, 100:2005-2011.
53. Matsumura T., Narimatsu H., Kami M., et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 2007, 13:577-583.
54. Montesinos P., Sanz J., Cantero S., et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009, 15:730-740.
55. Nakamura R., Battiwalla M., Solomon S., et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment. Biol Blood Marrow Transplant 2004, 10:49-57.
56. Bowden R.A., Digel J., Reed E.C., et al. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 1987, 156:899-903.
57. Naniche D., Oldstone M.B. Generalized immunosuppression: how viruses underline the immune response. Cell Mol Life Sci 2000, 57:1399-1407.
58. Tateda K., Ishii Y., Matsumoto T., Yamaguchi K. 'Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis 2006, 38:268-272.
59. Araoka H., Baba M., Takagi S., et al. Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'. Scand J Infect Dis 2010, 42:231-233.
60. Aoki N., Tateda K., Kikuchi Y., et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009, 63:534-542.
61. Montero M., Horcajada J.P., Sorli L., et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009, 37:461-465.
62. Marumo K., Komukai D., Hirose M., et al. Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP). J Infect Chemother 2012, 10.1007/s10156-012-0456-x.